Annexon (ANNX) EBITDA Margin: History & Chart

Annexon, Inc.(ANNX)

Biotechnology · Brisbane, CA

$4.20+0.01 (+0.24%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Annexon, Inc.

Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.

Brisbane, CA

92 employees

www.annexonbio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Douglas E. Love

View full financials

NAME	MARKET CAP	EBITDA MARGIN	TTM	3Y	5Y
Annexon, Inc. (ANNX)	$688.14M	N/A	N/A	N/A	N/A
Faeth Therapeutics, Inc. (FTH)vs ›	$698.60M	N/A	N/A	N/A	N/A
4D Molecular Therapeutics, Inc. (FDMT)vs ›	$675.41M	-178.29%	-244867.52%	-123424.79%	-82415.31%
Collegium Pharmaceutical, Inc. (COLL)vs ›	$709.33M	52.93%	53.31%	49.89%	44.80%
Achieve Life Sciences, Inc. (ACHV)vs ›	$719.64M	-414.93%	-258.43%	-185.54%	-212.52%
Aura Biosciences, Inc. (AURA)vs ›	$643.37M	N/A	N/A	N/A	N/A
AngioDynamics, Inc. (ANGO)vs ›	$642.31M	-5.39%	-5.12%	-17.61%	-12.23%
Anteris Technologies Global Corp. (AVR)vs ›	$734.10M	-4821.38%	-3832.53%	-2582.73%	-1806.92%
Fulgent Genetics, Inc. (FLGT)vs ›	$637.59M	-20.76%	-19.02%	-15.62%	12.71%
Climb Bio, Inc. (CLYM)vs ›	$632.76M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EBITDA MARGIN

TTM

Annexon, Inc. (ANNX)

$688.14M

N/A

Faeth Therapeutics, Inc. (FTH)vs ›

$698.60M

N/A

4D Molecular Therapeutics, Inc. (FDMT)vs ›

$675.41M